Top Markets
#1 Resolv wstUSR Resolv wstUSR +114.62%
#2 Luxxcoin Luxxcoin +45.27%
#3 ResearchCoin ResearchCoin +22.78%
#4 Reactive Network Reactive Network +20.67%
#5 Orderly Network Orderly Network +16.77%
#6 Layer3 Layer3 +13.71%
#7 Bitgert Bitgert +13.08%
#8 Aria.AI Aria.AI +11.86%
#9 Useless Coin Useless Coin +9.66%
#10 Lisk Bridged wstETH (Lisk) Lisk Bridged wstETH (Lisk) +9.53%
Coin of the day
Resolv wstUSR Resolv wstUSR
Setări
Limbă
ROMâNă
Monedă
USD
Temă
CSL Limited CSL Limited

CSL Limited

CSL
Rang în acțiuni #432
CSL Limited researches, develops, manufactures, markets, and distributes... CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Preț acțiune
$99.32
Capitalizare de piață
$48.20B
Schimbare (1 zi)
0.98%
Schimbare (1 an)
-32.14%
Țară
AU
Tranzacționează CSL Limited (CSL)

Categorie

Healthcare
Venituri pentru CSL Limited (CSL)
Venituri în Dec 2025 TTM: $15.70B
Conform celor mai recente rapoarte financiare ale CSL Limited, venitul actual al companiei (TTM) este $15.70B. În anul 2024, compania a avut un venit de $14.69B o creștere față de venitul din anul 2023, care a fost de $13.17B. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru CSL Limited din 2000 până în 2026
Venituri la sfârșitul fiecărui an
An Venituri Schimbă
2026 (TTM) $15.70B 1.72%
2025 $15.43B 5.04%
2024 $14.69B 11.51%
2023 $13.17B 25.55%
2022 $10.49B 1.56%
2021 $10.33B 9.84%
2020 $9.41B 13.08%
2019 $8.32B 11.54%
2018 $7.46B 6.28%
2017 $7.02B 15.81%
2016 $6.06B 11.00%
2015 $5.46B 8.91%
2014 $5.01B 10.79%
2013 $4.52B -2.44%
2012 $4.64B -3.37%
2011 $4.80B 49.63%
2010 $3.21B 6.25%
2009 $3.02B -7.53%
2008 $3.26B 42.87%
2007 $2.28B 45.52%
2006 $1.57B -1.58%
2005 $1.60B 98.59%
2004 $803.28M 36.45%
2003 $588.71M 38.88%
2002 $423.90M -2.21%
2001 $433.49M 0.00%
2000 0.00 0.00%
Venituri pentru companii similare sau concurente
Companie Venituri Diferență de venituri Țara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.55B 209.32%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B -23.30%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B -8.62%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B -42.13%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $5.49B -65.01%
NL